No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Spero Therapeutics (SPRO) Was Downgraded to a Hold Rating at Evercore ISI
Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug